GL1X · GenesisL1 explorer

Research workbench

Structure of BM3 heme domain in complex with troglitazone

Analyse Structure of BM3 heme domain in complex with troglitazone in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6HN8
Type
protein
Length
905 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Bifunctional cytochrome P450/NADPH--P450 reductase
EC
1.14.14.1, 1.6.2.4
UniProt
A0A1Q8UP87
Ligands
HEM, TDZ
Pockets
8 · best druggability 0.88

Structure

x-ray diffraction · 2 distinct chains · 54% helix, 11% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ABifunctional cytochrome P450/NADPH--P450 reductase (EC 1.14.14.1, 1.6.2.4)protein45354% helix, 11% strandA0A1Q8UP87
BBifunctional cytochrome P450/NADPH--P450 reductase (EC 1.14.14.1, 1.6.2.4)protein45254% helix, 11% strandA0A1Q8UP87

Ligands and binding sites

  • HEM · Protoporphyrin IX containing Fe · ligand · 2 copies · chains A, B
  • TDZ · (5R)-5-(4-{[(2R)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 6 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
17180.880.9177HEM, TDZ
27180.870.9176HEM, TDZ
310240.800.8174empty
42470.600.8031empty
51470.560.8226empty

Interfaces

1 interface between chains.

  • A–B · 789 Ų buried · 4 hydrogen bonds · protein-protein

Compared structures

  • 6HN8 · Structure of BM3 heme domain in complex with troglitazone · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.